IRIS Accounts Production v23.3.1.45 06794267 Board of Directors 1.4.22 31.3.23 31.3.23 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh067942672022-03-31067942672023-03-31067942672022-04-012023-03-31067942672021-03-31067942672021-04-012022-03-31067942672022-03-3106794267ns10:Originalns15:EnglandWales2022-04-012023-03-3106794267ns14:PoundSterlingns10:Original2022-04-012023-03-3106794267ns10:Originalns10:Director12022-04-012023-03-3106794267ns10:Original2022-04-012023-03-3106794267ns10:Original2023-03-3106794267ns10:Originalns10:PrivateLimitedCompanyLtd2022-04-012023-03-3106794267ns10:Originalns10:SmallEntities2022-04-012023-03-3106794267ns10:Originalns10:AuditExempt-NoAccountantsReport2022-04-012023-03-3106794267ns10:Originalns10:SmallCompaniesRegimeForDirectorsReport2022-04-012023-03-3106794267ns10:SmallCompaniesRegimeForAccountsns10:Original2022-04-012023-03-3106794267ns10:Originalns10:FullAccounts2022-04-012023-03-3106794267ns10:Original2022-03-3106794267ns10:Originalns5:CurrentFinancialInstruments2023-03-3106794267ns10:Originalns5:CurrentFinancialInstruments2022-03-3106794267ns10:Originalns5:Non-currentFinancialInstruments2023-03-3106794267ns10:Originalns5:Non-currentFinancialInstruments2022-03-3106794267ns5:ShareCapitalns10:Original2023-03-3106794267ns5:ShareCapitalns10:Original2022-03-3106794267ns10:Originalns5:RetainedEarningsAccumulatedLosses2023-03-3106794267ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-03-3106794267ns10:Originalns10:RegisteredOffice2022-04-012023-03-3106794267ns10:Original2021-04-012022-03-3106794267ns10:Originalns5:PlantMachinery2022-03-3106794267ns10:Originalns5:PlantMachinery2022-04-012023-03-3106794267ns10:Originalns5:PlantMachinery2023-03-3106794267ns10:Originalns5:PlantMachinery2022-03-3106794267ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-03-3106794267ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-03-3106794267ns10:Originalns5:WithinOneYear2023-03-3106794267ns10:Originalns5:WithinOneYear2022-03-31
REGISTERED NUMBER: 06794267 (England and Wales)









Unaudited Financial Statements

for the Year Ended 31 March 2023

for

Plazology Ltd

Plazology Ltd (Registered number: 06794267)






Contents of the Financial Statements
for the Year Ended 31 March 2023




Page

Balance Sheet 1

Notes to the Financial Statements 3


Plazology Ltd (Registered number: 06794267)

Balance Sheet
31 March 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 98,370 115,293

CURRENT ASSETS
Debtors 5 19,569 79,533
Cash at bank 132,323 47,822
151,892 127,355
CREDITORS
Amounts falling due within one year 6 83,644 115,960
NET CURRENT ASSETS 68,248 11,395
TOTAL ASSETS LESS CURRENT
LIABILITIES

166,618

126,688

CREDITORS
Amounts falling due after more than one
year

7

(14,668

)

(42,123

)

PROVISIONS FOR LIABILITIES (18,659 ) (21,871 )
NET ASSETS 133,291 62,694

CAPITAL AND RESERVES
Called up share capital 9 2 2
Retained earnings 133,289 62,692
SHAREHOLDERS' FUNDS 133,291 62,694

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Plazology Ltd (Registered number: 06794267)

Balance Sheet - continued
31 March 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 17 November 2023 and were signed on its behalf by:





Mr S D Mollon - Director


Plazology Ltd (Registered number: 06794267)

Notes to the Financial Statements
for the Year Ended 31 March 2023

1. STATUTORY INFORMATION

Plazology Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 06794267

Registered office: 1200 Century Way
Thorpe Park Business Park
Colton
Leeds
West Yorkshire
LS15 8ZA

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in UK and Republic of Ireland" and the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to give a true and fair view.

The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts and value added tax.

Turnover from the supply of services represents the value of services provided under contracts to the extent that there is a right to consideration and is recorded at the fair value of the consideration received or receivable. Where a contract has only been partially completed at the balance sheet date turnover represents the fair value of the service provided to date based on the stage of completion and the contract activity at the balance sheet date. Where payments are received from customers in advance of services provided, the amounts are recorded as deferred income and included as part of creditors due within one year.

Tangible fixed assets
Tangible fixed assets are stated at purchase cost, net of depreciation.

Depreciation is provided on all tangible assets at rates calculated to write off the cost less estimated residual value of each asset on a straight line basis over its expected useful life as follows:

Plant and machinery- 25% on cost, 20% on cost and 10% on cost
Fixtures and fittings- 33% on cost
Computer equipment- 33% on cost

Residual value represents the estimated amount which would currently be obtained from disposal of an asset after deducting estimated costs of disposal, if the asset were already at an age and in the condition expected at the end of its estimated useful life.

The gain or loss arising on the disposal of an asset is determined on the difference between the sale proceeds and the carrying value of the asset, and is recognised in the profit and loss account.


Plazology Ltd (Registered number: 06794267)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2023

2. ACCOUNTING POLICIES - continued
Taxation
Current tax, including UK corporation tax is provided at amounts expected to be paid (or recovered) using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events that result in an obligation to pay more tax in the future or a right to pay less tax in the future have occurred at the balance sheet date. Timing differences are differences between the company's taxable profits and its results as stated in the financial statements that arise from the inclusion of gains and losses in tax assessments in periods different from those in which they are recognised in the financial statements.

Leasing commitments
Rentals under operating leases are charged on a straight-line basis over the lease term, even if the payments are not made on such basis. Benefits received and receivable as an incentive to sign an operating lease are similarly spread on a straight-line basis over the lease term.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Government grants
Government grants are recognised based on the accrual model and are measured at the fair value of the asset received or receivable. Grants are classified as relating either to revenue or to assets. Grants relating to revenue are recognised in income over the period in which the related costs are recognised.

Dividends
Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an Annual General Meeting.

Financial instruments
Financial assets and financial liabilities are recognised when the company becomes a party to the contractual provisions of the instrument.

All financial assets and liabilities are initially measured at transaction price (including transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

The following assets and liabilities are classified as basic financial instruments - trade debtors, other debtors, cash and bank balances, trade creditors and other creditors.

Trade debtors, other debtors, cash and bank balances, trade creditors and other creditors are measured at the amortised cost equivalent to the undiscounted amount of cash or other consideration expected to be paid or received.

Plazology Ltd (Registered number: 06794267)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2023

2. ACCOUNTING POLICIES - continued

Impairment of assets
Assets are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit and loss as described below.

Non financial assets
An asset is impaired when there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

Financial assets
For financial assets carried at cost less impairment, the impairment loss is the difference between the asset's carrying amount and the best estimate of the amount that would be received for the asset if it were sold at the reporting date.

Where indicators exist for a decrease in impairment loss, and the decrease can be related objectively to an event occurring after the impairment was recognised, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired financial asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had the impairment loss not been recognised.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 5 (2022 - 6 ) .

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 April 2022 200,274
Additions 3,429
At 31 March 2023 203,703
DEPRECIATION
At 1 April 2022 84,981
Charge for year 20,352
At 31 March 2023 105,333
NET BOOK VALUE
At 31 March 2023 98,370
At 31 March 2022 115,293

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade debtors 11,880 58,120
Amounts recoverable on contract - 6,103
Other debtors 7,689 15,310
19,569 79,533

Plazology Ltd (Registered number: 06794267)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2023

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade creditors 10,281 69,227
Taxation and social security 40,662 5,395
Other creditors 32,701 41,338
83,644 115,960

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2023 2022
£    £   
Other creditors 14,668 42,123

8. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
2023 2022
£    £   
Within one year 14,553 13,881

9. CALLED UP SHARE CAPITAL

2023 2022
£ £
Allotted, issued and fully paid 2 2